Evidence map›Paper›PMID 25231994›Full record

ArticleThe Journal of biological chemistry2014

Down-regulation of cyclooxygenase-2 by the carboxyl tail of the angiotensin II type 1 receptor.

Rapita Sood, Waleed Minzel, Gilad Rimon, Sharon Tal, Liza Barki-Harrington

Erratum issuedOpen access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
  3. Expression and Significance of COX-2 and Ki-67 in Hepatolithiasis with Bile Duct Carcinoma.Medical science monitor : international medical journal of experimental and clinical research · 2015
    Article
  4. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Rapita SoodFrom the Department of Human Biology, Faculty of Natural Sciences, University of Haifa, Haifa, Israel 3498838 and.
Waleed MinzelFrom the Department of Human Biology, Faculty of Natural Sciences, University of Haifa, Haifa, Israel 3498838 and.
Gilad RimonDepartment of Clinical Biochemistry and Pharmacology, Faculty of Health Sciences, Ben-Gurion University of the Negev, Be'er-Sheva 84105, Israel.
Sharon TalFrom the Department of Human Biology, Faculty of Natural Sciences, University of Haifa, Haifa, Israel 3498838 and.
Liza Barki-HarringtonFrom the Department of Human Biology, Faculty of Natural Sciences, University of Haifa, Haifa, Israel 3498838 and lbarki@psy.haifa.ac.il.
University of Haifa · ILBen-Gurion University of the Negev · IL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The enzyme cyclooxygenase-2 (COX-2) plays an important role in the kidney by up-regulating the production of the vasoconstrictor hormone angiotensin II (AngII), which in turn down-regulates COX-2 expression via activation of the angiotensin II type 1 receptor (AT1) receptor. Chemical inhibition of the catalytic activity of COX-2 is a well-established strategy for treating inflammation but little is known of cellular mechanisms that dispose of the protein itself. Here we show that in addition to its indirect negative feedback on COX-2, AT1 also down-regulates the expression of the COX-2 protein via a pathway that does not involve G-protein or β-arrestin-dependent signaling. Instead, AT1 enhances the ubiquitination and subsequent degradation of the enzyme in the proteasome through elements in its cytosolic carboxyl tail (CT). We find that a mutant receptor that lacks the last 35 amino acids of its CT (Δ324) is devoid of its ability to reduce COX-2, and that expression of the CT sequence alone is sufficient to down-regulate COX-2. Collectively these results propose a new role for AT1 in regulating COX-2 expression in a mechanism that deviates from its canonical signaling pathways. Down-regulation of COX-2 by a short peptide that originates from AT1 may present as a basis for novel therapeutic means of eliminating excess COX-2 protein.

Indexed as

Down-RegulationAmino Acid MotifsBacterial ProteinsCatalytic DomainCloning, MolecularCyclooxygenase 2Gene Expression Regulation, EnzymologicHEK293 CellsHumansInflammationLuminescent ProteinsMutationProteasome Endopeptidase ComplexRadioimmunoassayReceptor, Angiotensin, Type 1Signal TransductionBacterial ProteinsCyclooxygenase 2Luminescent ProteinsProteasome Endopeptidase ComplexPTGS2 protein, humanReceptor, Angiotensin, Type 1yellow fluorescent protein, BacteriaAngiotensin IIG Protein-coupled Receptor (GPCR)ProteasomeProtein DegradationProtein Motif

Identifiers

PMID25231994
PMCPMC4223345
OpenAlexW2048266313

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.